PSNL 8-K
Personalis, Inc. (PSNL)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2020
Personalis, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware |
001-38943 |
27-5411038 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
1330 O’Brien Drive Menlo Park, California 94025 |
|
94025 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
(650) 752-1300
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, $0.0001 par value per share |
|
PSNL |
|
The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2020, Personalis, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2020. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
|
Description |
|
99.1 |
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
Date: August 6, 2020 |
|
Personalis, Inc. |
|
|
|
|
|
|
|
|
|
By: |
/s/ Aaron Tachibana |
|
|
|
|
Aaron Tachibana |
|
|
|
|
Chief Financial Officer |
Exhibit 99.1
Personalis Reports Second Quarter 2020 Financial Results
MENLO PARK, Calif. – August 6, 2020 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the second quarter ended June 30, 2020.
Second Quarter Highlights
|
|
• |
Reported record revenues of $19.5 million in the second quarter of 2020 versus $15.8 million in the second quarter of 2019, an increase of 23% |
|
|
• |
A total of 32 customers have placed orders for NeXT as of June 30, 2020, with 6 of those customers placing their first orders in the second quarter of 2020 |
|
|
• |
Announced a collaboration with Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a leader in precision genetic medicine for rare disease |
|
|
• |
Announced expansion plans into China along with a partnership with Berry Genomics, who will provide services and support to Personalis |
|
|
• |
Achieved milestone of completing the 75,000th whole human genome sequenced under the contract with the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) |
“I’m proud to say that we were able to report record revenues once again this quarter, with our team delivering strong execution across both our population sequencing and biopharma businesses, despite the impact from the COVID-19 pandemic, and we continued to see strong ordering levels from both our existing and new customers,” said John West, Chief Executive Officer. “In addition, our recently announced liquid biopsy product will be available to order immediately.”
Second Quarter 2020 Financial Results
Revenues were $19.5 million in the three months ended June 30, 2020, up 23.2% from $15.8 million in the same period of the prior year. In the second quarter, the VA MVP accounted for $14.8 million of our total revenues, and the remaining $4.7 million was from biopharmaceutical and all other customers.
Gross margin was 24.0% for the three months ended June 30, 2020, compared with 37.3% in the same period of the prior year.
Operating expenses were $14.2 million for the three months ended June 30, 2020, compared with $10.0 million in the same period of the prior year.
Net loss was $9.3 million for the three months ended June 30, 2020 and net loss per share was $0.29 based on a weighted-average basic and diluted share count of 31.7 million, compared with a net loss of $5.9 million and a net loss per share of $0.89 based on a weighted-average basic and diluted share count of 6.6 million in the same period of the prior year.
1
Cash, cash equivalents, and short-term investments were $105.2 million as of June 30, 2020.
Outlook and COVID-19
Due to continued uncertainty surrounding the COVID-19 pandemic, Personalis will not provide an outlook for fiscal 2020 at this time and will plan to give an update during its third quarter earnings announcement and press release, to the extent practicable, based on available information at that time.
Webcast and Conference Call Information
Personalis will host a conference call to discuss the second quarter financial results after market close on Thursday, August 6, 2020 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The conference call can be accessed live over the phone (866) 220-8061 for U.S. callers or (470) 495-9168 for international callers, using conference ID: 4682918. The live webinar can be accessed at https://investors.personalis.com.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue or blood sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors relate to, among others: the timing and pace of new orders from customers; the launch of our new liquid biopsy product and customer adoption of such new products; the timing of tissue and blood sample receipts from customers, which can materially impact revenue quarter over quarter and year over year; whether orders for the NeXT platform® and revenues from biopharmaceutical customers will increase; the success of our collaborations and partnerships, including with Sarepta Therapeutics and Berry Genomics; the success of our international expansion plans; the evolution of cancer therapies and market adoption of our services; our expectations regarding future performance; and the COVID-19 pandemic, which may significantly impact our business and operations and the business and operations of our customers. In addition, other potential risks and uncertainties that could cause actual results to differ from the results predicted
2
include, among others, those risks and uncertainties included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Quarterly Report on Form 10-Q for the period ended June 30, 2020, that will be filed following this earnings release. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
Contacts:
Investor Relations Contact:
Caroline Corner
415-202-5678
Media Contact:
Jennifer Havlek
www.personalis.com
650-752-1300
3
PERSONALIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
(in thousands, except share and per share data)
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
|
June 30, |
|
|
June 30, |
|
||||||||||
|
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
|
Revenues |
|
$ |
19,495 |
|
|
$ |
15,825 |
|
|
$ |
38,656 |
|
|
$ |
29,900 |
|
|
Costs and expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs of revenues |
|
|
14,823 |
|
|
|
9,923 |
|
|
|
29,945 |
|
|
|
20,014 |
|
|
Research and development |
|
|
6,465 |
|
|
|
4,497 |
|
|
|
12,855 |
|
|
|
9,742 |
|
|
Selling, general and administrative |
|
|
7,705 |
|
|
|
5,466 |
|
|
|
14,979 |
|
|
|
9,636 |
|
|
Total costs and expenses |
|
|
28,993 |
|
|
|
19,886 |
|
|
|
57,779 |
|
|
|
39,392 |
|
|
Loss from operations |
|
|
(9,498 |
) |
|
|
(4,061 |
) |
|
|
(19,123 |
) |
|
|
(9,492 |
) |
|
Interest income |
|
|
246 |
|
|
|
200 |
|
|
|
756 |
|
|
|
284 |
|
|
Interest expense |
|
|
— |
|
|
|
(745 |
) |
|
|
(2 |
) |
|
|
(929 |
) |
|
Other income (expense), net |
|
|
1 |
|
|
|
(1,261 |
) |
|
|
9 |
|
|
|
(1,413 |
) |
|
Loss before income taxes |
|
|
(9,251 |
) |
|
|
(5,867 |
) |
|
|
(18,360 |
) |
|
|
(11,550 |
) |
|
Provision for income taxes |
|
|
(4 |
) |
|
|
(2 |
) |
|
|
(34 |
) |
|
|
(4 |
) |
|
Net loss |
|
$ |
(9,255 |
) |
|
$ |
(5,869 |
) |
|
$ |
(18,394 |
) |
|
$ |
(11,554 |
) |
|
Net loss per share, basic and diluted |
|
$ |
(0.29 |
) |
|
$ |
(0.89 |
) |
|
$ |
(0.58 |
) |
|
$ |
(2.38 |
) |
|
Weighted-average shares outstanding, basic and diluted |
|
|
31,731,628 |
|
|
|
6,597,007 |
|
|
|
31,538,329 |
|
|
|
4,853,325 |
|
4
SUPPLEMENTAL REVENUE INFORMATION (unaudited)
(in thousands)
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
|
VA MVP |
|
$ |
14,750 |
|
|
$ |
8,536 |
|
|
$ |
29,506 |
|
|
$ |
16,879 |
|
|
All other customers |
|
|
4,745 |
|
|
|
7,289 |
|
|
|
9,150 |
|
|
|
13,021 |
|
|
Total |
|
$ |
19,495 |
|
|
$ |
15,825 |
|
|
$ |
38,656 |
|
|
$ |
29,900 |
|
5
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in thousands, except share and per share data)
|
|
|
June 30, |
|
|
December 31, |
|
||
|
|
|
2020 |
|
|
2019 |
|
||
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
25,042 |
|
|
$ |
55,046 |
|
|
Short-term investments |
|
|
80,191 |
|
|
|
73,243 |
|
|
Accounts receivable, net |
|
|
5,375 |
|
|
|
3,300 |
|
|
Inventory and other deferred costs |
|
|
6,524 |
|
|
|
4,606 |
|
|
Prepaid expenses and other current assets |
|
|
2,989 |
|
|
|
3,383 |
|
|
Total current assets |
|
|
120,121 |
|
|
|
139,578 |
|
|
Property and equipment, net |
|
|
12,650 |
|
|
|
14,106 |
|
|
Operating lease right-of-use assets |
|
|
10,991 |
|
|
|
1,845 |
|
|
Other long-term assets |
|
|
1,760 |
|
|
|
1,762 |
|
|
Total assets |
|
$ |
145,522 |
|
|
$ |
157,291 |
|
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
7,491 |
|
|
$ |
7,337 |
|
|
Accrued and other current liabilities |
|
|
6,594 |
|
|
|
6,648 |
|
|
Contract liabilities |
|
|
28,952 |
|
|
|
35,977 |
|
|
Total current liabilities |
|
|
43,037 |
|
|
|
49,962 |
|
|
Long-term operating lease liabilities |
|
|
9,233 |
|
|
|
639 |
|
|
Other long-term liabilities |
|
|
129 |
|
|
|
— |
|
|
Total liabilities |
|
|
52,399 |
|
|
|
50,601 |
|
|
Commitments and Contingencies |
|
|
|
|
|
|
|
|
|
Stockholders’ equity |
|
|
|
|
|
|
|
|
|
Preferred stock, $0.0001 par value — 10,000,000 shares authorized; none issued |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.0001 par value — 200,000,000 shares authorized; 31,872,122 and 31,243,029 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively |
|
|
3 |
|
|
|
3 |
|
|
Additional paid-in capital |
|
|
251,997 |
|
|
|
247,282 |
|
|
Accumulated other comprehensive income (loss) |
|
|
106 |
|
|
|
(6 |
) |
|
Accumulated deficit |
|
|
(158,983 |
) |
|
|
(140,589 |
) |
|
Total stockholders’ equity |
|
|
93,123 |
|
|
|
106,690 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
145,522 |
|
|
$ |
157,291 |
|